CyDex, Prism Pharmaceuticals deal

CyDex and Prism mutually terminated a deal to develop an IV formulation of clopidogrel using CyDex's Captisol sulfobutylether beta-cyclodextrin technology. The program has completed a Phase I/II trial in acute coronary syndrome (ACS). CyDex said it will seek a partner to continue development of the adenosine diphosphate (ADP) receptor (P2Y12) antagonist. CyDex said the product is being developed under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from scientific literature or from previously approved products. Further terms were not disclosed. ...